Marker expression in peripheral T-cell lymphoma

A proposed clinical-pathologic prognostic score

Philip Went, Claudio Agostinelli, Andrea Gallamini, Pier Paolo Piccaluga, Stefano Ascani, Elena Sabattini, Francesco Bacci, Brunangelo Falini, Teresio Motta, Marco Paulli, Tullio Artusi, Milena Piccioli, Pier Luigi Zinzani, Stefano A. Pileri

Research output: Contribution to journalArticle

251 Citations (Scopus)

Abstract

Purpose: Although peripheral T-cell lymphoma, unspecified (PTCL/U), is the most common T-cell tumor in Western countries, no study to date has been based on the application of a wide panel of markers to a large series of patients and assessed the impact of phenotype on survival. We evaluated the expression of 19 markers in 148 PTCLs/U and 45 PTCLs of the angioimmunoblastic type (AILD). Patients and Methods: The analysis was performed on tissue microarrays by immunohistochemistry and in situ hybridization. Clinical data were available in 93 PTCL/U patients, most of whom had been included in a previous study proposing a prognostic index (PIT). Results: An aberrant phenotype with frequent loss of CD5 and/or CD7 was typical for PTCLs, irrespective of whether they were U or AILD. Aberrantly expressed proteins rarely included CD20, CD15, and CD30. Positivity for Epstein-Barr virus-associated small RNAs and CD15 expression emerged as adverse prognostic factors. Among PTCLs/U, the proliferation- associated protein Ki-67 turned out to be prognostically relevant and was integrated in a new predictive score, incorporating age (> 60 years), high lactate dehydrogenase, poor performance status, and Ki-67 ≥ 80%. This score was associated with the patient outcome (P <.0001) and was found to be more robust than PIT (P = .0043) in the present series. Conclusion: Our retrospective analysis shows a wide range of protein expression in PTCLs and proposes a new prognostic index. The latter represents one of the first examples of mixed score (including patient-and tumor-specific factors) applied to malignant lymphomas and may be the basis for future prospective therapeutic trials.

Original languageEnglish
Pages (from-to)2472-2479
Number of pages8
JournalJournal of Clinical Oncology
Volume24
Issue number16
DOIs
Publication statusPublished - Jun 1 2006

Fingerprint

Peripheral T-Cell Lymphoma
Phenotype
Proteins
Human Herpesvirus 4
L-Lactate Dehydrogenase
In Situ Hybridization
Lymphoma
Neoplasms
Immunohistochemistry
RNA
T-Lymphocytes
Survival

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Marker expression in peripheral T-cell lymphoma : A proposed clinical-pathologic prognostic score. / Went, Philip; Agostinelli, Claudio; Gallamini, Andrea; Piccaluga, Pier Paolo; Ascani, Stefano; Sabattini, Elena; Bacci, Francesco; Falini, Brunangelo; Motta, Teresio; Paulli, Marco; Artusi, Tullio; Piccioli, Milena; Zinzani, Pier Luigi; Pileri, Stefano A.

In: Journal of Clinical Oncology, Vol. 24, No. 16, 01.06.2006, p. 2472-2479.

Research output: Contribution to journalArticle

Went, P, Agostinelli, C, Gallamini, A, Piccaluga, PP, Ascani, S, Sabattini, E, Bacci, F, Falini, B, Motta, T, Paulli, M, Artusi, T, Piccioli, M, Zinzani, PL & Pileri, SA 2006, 'Marker expression in peripheral T-cell lymphoma: A proposed clinical-pathologic prognostic score', Journal of Clinical Oncology, vol. 24, no. 16, pp. 2472-2479. https://doi.org/10.1200/JCO.2005.03.6327
Went P, Agostinelli C, Gallamini A, Piccaluga PP, Ascani S, Sabattini E et al. Marker expression in peripheral T-cell lymphoma: A proposed clinical-pathologic prognostic score. Journal of Clinical Oncology. 2006 Jun 1;24(16):2472-2479. https://doi.org/10.1200/JCO.2005.03.6327
Went, Philip ; Agostinelli, Claudio ; Gallamini, Andrea ; Piccaluga, Pier Paolo ; Ascani, Stefano ; Sabattini, Elena ; Bacci, Francesco ; Falini, Brunangelo ; Motta, Teresio ; Paulli, Marco ; Artusi, Tullio ; Piccioli, Milena ; Zinzani, Pier Luigi ; Pileri, Stefano A. / Marker expression in peripheral T-cell lymphoma : A proposed clinical-pathologic prognostic score. In: Journal of Clinical Oncology. 2006 ; Vol. 24, No. 16. pp. 2472-2479.
@article{e1f470780fea44a1a00c1131e6e5cacd,
title = "Marker expression in peripheral T-cell lymphoma: A proposed clinical-pathologic prognostic score",
abstract = "Purpose: Although peripheral T-cell lymphoma, unspecified (PTCL/U), is the most common T-cell tumor in Western countries, no study to date has been based on the application of a wide panel of markers to a large series of patients and assessed the impact of phenotype on survival. We evaluated the expression of 19 markers in 148 PTCLs/U and 45 PTCLs of the angioimmunoblastic type (AILD). Patients and Methods: The analysis was performed on tissue microarrays by immunohistochemistry and in situ hybridization. Clinical data were available in 93 PTCL/U patients, most of whom had been included in a previous study proposing a prognostic index (PIT). Results: An aberrant phenotype with frequent loss of CD5 and/or CD7 was typical for PTCLs, irrespective of whether they were U or AILD. Aberrantly expressed proteins rarely included CD20, CD15, and CD30. Positivity for Epstein-Barr virus-associated small RNAs and CD15 expression emerged as adverse prognostic factors. Among PTCLs/U, the proliferation- associated protein Ki-67 turned out to be prognostically relevant and was integrated in a new predictive score, incorporating age (> 60 years), high lactate dehydrogenase, poor performance status, and Ki-67 ≥ 80{\%}. This score was associated with the patient outcome (P <.0001) and was found to be more robust than PIT (P = .0043) in the present series. Conclusion: Our retrospective analysis shows a wide range of protein expression in PTCLs and proposes a new prognostic index. The latter represents one of the first examples of mixed score (including patient-and tumor-specific factors) applied to malignant lymphomas and may be the basis for future prospective therapeutic trials.",
author = "Philip Went and Claudio Agostinelli and Andrea Gallamini and Piccaluga, {Pier Paolo} and Stefano Ascani and Elena Sabattini and Francesco Bacci and Brunangelo Falini and Teresio Motta and Marco Paulli and Tullio Artusi and Milena Piccioli and Zinzani, {Pier Luigi} and Pileri, {Stefano A.}",
year = "2006",
month = "6",
day = "1",
doi = "10.1200/JCO.2005.03.6327",
language = "English",
volume = "24",
pages = "2472--2479",
journal = "Journal of Clinical Oncology",
issn = "0732-183X",
publisher = "American Society of Clinical Oncology",
number = "16",

}

TY - JOUR

T1 - Marker expression in peripheral T-cell lymphoma

T2 - A proposed clinical-pathologic prognostic score

AU - Went, Philip

AU - Agostinelli, Claudio

AU - Gallamini, Andrea

AU - Piccaluga, Pier Paolo

AU - Ascani, Stefano

AU - Sabattini, Elena

AU - Bacci, Francesco

AU - Falini, Brunangelo

AU - Motta, Teresio

AU - Paulli, Marco

AU - Artusi, Tullio

AU - Piccioli, Milena

AU - Zinzani, Pier Luigi

AU - Pileri, Stefano A.

PY - 2006/6/1

Y1 - 2006/6/1

N2 - Purpose: Although peripheral T-cell lymphoma, unspecified (PTCL/U), is the most common T-cell tumor in Western countries, no study to date has been based on the application of a wide panel of markers to a large series of patients and assessed the impact of phenotype on survival. We evaluated the expression of 19 markers in 148 PTCLs/U and 45 PTCLs of the angioimmunoblastic type (AILD). Patients and Methods: The analysis was performed on tissue microarrays by immunohistochemistry and in situ hybridization. Clinical data were available in 93 PTCL/U patients, most of whom had been included in a previous study proposing a prognostic index (PIT). Results: An aberrant phenotype with frequent loss of CD5 and/or CD7 was typical for PTCLs, irrespective of whether they were U or AILD. Aberrantly expressed proteins rarely included CD20, CD15, and CD30. Positivity for Epstein-Barr virus-associated small RNAs and CD15 expression emerged as adverse prognostic factors. Among PTCLs/U, the proliferation- associated protein Ki-67 turned out to be prognostically relevant and was integrated in a new predictive score, incorporating age (> 60 years), high lactate dehydrogenase, poor performance status, and Ki-67 ≥ 80%. This score was associated with the patient outcome (P <.0001) and was found to be more robust than PIT (P = .0043) in the present series. Conclusion: Our retrospective analysis shows a wide range of protein expression in PTCLs and proposes a new prognostic index. The latter represents one of the first examples of mixed score (including patient-and tumor-specific factors) applied to malignant lymphomas and may be the basis for future prospective therapeutic trials.

AB - Purpose: Although peripheral T-cell lymphoma, unspecified (PTCL/U), is the most common T-cell tumor in Western countries, no study to date has been based on the application of a wide panel of markers to a large series of patients and assessed the impact of phenotype on survival. We evaluated the expression of 19 markers in 148 PTCLs/U and 45 PTCLs of the angioimmunoblastic type (AILD). Patients and Methods: The analysis was performed on tissue microarrays by immunohistochemistry and in situ hybridization. Clinical data were available in 93 PTCL/U patients, most of whom had been included in a previous study proposing a prognostic index (PIT). Results: An aberrant phenotype with frequent loss of CD5 and/or CD7 was typical for PTCLs, irrespective of whether they were U or AILD. Aberrantly expressed proteins rarely included CD20, CD15, and CD30. Positivity for Epstein-Barr virus-associated small RNAs and CD15 expression emerged as adverse prognostic factors. Among PTCLs/U, the proliferation- associated protein Ki-67 turned out to be prognostically relevant and was integrated in a new predictive score, incorporating age (> 60 years), high lactate dehydrogenase, poor performance status, and Ki-67 ≥ 80%. This score was associated with the patient outcome (P <.0001) and was found to be more robust than PIT (P = .0043) in the present series. Conclusion: Our retrospective analysis shows a wide range of protein expression in PTCLs and proposes a new prognostic index. The latter represents one of the first examples of mixed score (including patient-and tumor-specific factors) applied to malignant lymphomas and may be the basis for future prospective therapeutic trials.

UR - http://www.scopus.com/inward/record.url?scp=33744992010&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33744992010&partnerID=8YFLogxK

U2 - 10.1200/JCO.2005.03.6327

DO - 10.1200/JCO.2005.03.6327

M3 - Article

VL - 24

SP - 2472

EP - 2479

JO - Journal of Clinical Oncology

JF - Journal of Clinical Oncology

SN - 0732-183X

IS - 16

ER -